Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends

Dec 11, 2025World journal of gastrointestinal pharmacology and therapeutics

Overview of treatments, targets, and trends for fatty liver disease linked to metabolism problems

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver disease globally.

MASLD is closely associated with type 2 diabetes, cardiovascular disease, and metabolic dysfunction.
Its progression involves insulin resistance, fat toxicity, imbalances in gut bacteria, and disrupted signaling pathways.
Current pharmacological treatments for MASLD are limited, with Resmetirom being the only approved medication for related conditions.
Off-label use of vitamin E and obeticholic acid has shown some treatment success.
Emerging agents like PPAR agonists and novel antidiabetic drugs have demonstrated promise, but further evidence is required.
Concerns exist regarding the efficacy of metformin and potential liver damage from statins.

AI simplified

Metabolic dysfunction-associated steatotic liver disease (MASLD), recognized as the most prevalent liver disease worldwide and a leading cause of liver transplantation, is closely associated with type 2 diabetes, cardiovascular disease, and metabolic dysfunction. Its multifactorial pathogenesis involves insulin resistance, lipotoxicity, gut dysbiosis, and dysregulated signaling involving multiple receptors and pathways, culminating in hepatic steatosis, inflammation, fibrosis, and, ultimately, cirrhosis. Emerging insights into bile acid metabolism, short-chain fatty acids, and fibrogenic mediators underscore the complexity of disease progression. Despite increasing global prevalence, effective pharmacological treatments remain limited. Resmetirom, a thyroid hormone receptor β (THR-β) agonist, is currently the lone agent approved for treating metabolic dysfunction-associated steatohepatitis (MASH). Off-label use of vitamin E and obeticholic acid has met with some treatment success. Peroxisome proliferator-activated receptor (PPAR) agonists, novel antidiabetic agents, glucagon-like peptide 1 agonists, and sodium-glucose cotransporter 2 inhibitors have shown promising results in MASLD/MASH; however, further data are needed to prove their efficacy and safety. While metformin has largely failed to demonstrate efficacy, hepatotoxicity remains an area of concern with statin therapy. Novel agents, such as fibroblast growth factor analogs, fatty acid synthase inhibitors, galectin-3 inhibitors, and stearoyl-CoA desaturase inhibitors, are in the early stages of development and trials, warranting further research in steatotic liver diseases. Despite encouraging advances, long-term safety, durability of response, and regulatory approvals remain key hurdles before these agents can be broadly implemented in clinical practice. This review summarizes current knowledge on the pathogenesis of MASLD/MASH and the molecular pathways that may offer therapeutic potential in managing this widespread metabolic liver disease.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (HTML) ↗View full text ↗

Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief